Pharmaceutical Sales Force Effectiveness Strategies
Evaluating evolving sales models & advanced technology for a customer centric approach

By Dr Ksenija Jakovcic
Dr Ksenija Jakovcic

Ksenija Jakovcic is Business Development Manager at SanMed, and provides independent consulting services to the pharmaceutical and biotechnology industry. Following her medical practice, Ksenija has worked with international pharmaceutical companies in Austria and the UK around the areas of clinical research and sales & marketing. Ksenija holds an MD from the University of Vienna, Austria and an MBA from the London Business School.
Table of Contents

Pharmaceutical Sales Force Effectiveness Strategies

Executive Summary 9

- The pharmaceutical industry at a crossroads 9
- Sizing and structuring the sales force for strategic advantage 10
- Recruiting, training and motivating an outstanding sales force 11
- Reinventing the pharmaceutical sales model 12
- Utilizing new technologies for sales excellence 13
- Beyond 2010 – The future of pharmaceutical sales 14

Chapter 1 The pharmaceutical industry at a crossroads 16

Summary 16

Introduction 17

- The state of the pharmaceutical industry 18
  - Patent expiration and generic substitution 18
  - Pipelines not delivering innovative products 20
  - Slowing growth in mature markets 23
  - Government intervention and price controls 25
  - Poor reputation and new restrictions 26
    - Restricted access for pharmaceutical sales representatives 27
    - Pharma industry revises Codes on interactions with physicians 29
- The traditional go-to-market strategy 31
  - ROI in pharmaceutical sales force has plummeted 32
  - The access problem 34
  - The end of armies of pharma sales reps in the field 34
- Need for new marketing and sales approaches 36
Chapter 2  Sizing and structuring the sales force for strategic advantage 40

Summary 40
Introduction 41
The role of the sales force 41
Determining sales force size 42
Activity-based method 42
Target return-per-call method 43
Sales response method 44
Getting sales force deployment right 45
Resource allocation 45
Optimal profitability 46
Matching sales force structure with companies’ business lifecycle 48
Sales force structure 48
Getting the size right 50
From mass market endeavor to individual physicians’ needs 51
Rethinking targeting strategy 51
The impact of lifecycle factors on sales force targeting 55
Year 1 – New product launch 55
Year 2 – Accelerate growth 56
Year 3 – Defend and grow 56
Year 8 – Manage the sales decline 58
Conclusion 59

Chapter 3  Recruiting, training & motivating an outstanding sales force 62

Summary 62
Introduction 63
Hiring pharma sales reps: Getting the process right 64
The impact of bad hiring decisions 64
The right recruit 65
Key points to consider when hiring 67
The evolving training needs of the pharma sales force 69
The training dilemma 70
Training for the new environment 72
Changing environment places different demands on sales training 75
Motivating and compensating the sales force 79
Motivation 80
Driving performance through incentive compensation plans 82
Conclusion 83
Will samples need pharmaceutical sales reps? 123

New industry models and their implications for sales force effectiveness 125
Aligning marketing and sales to match the healthcare environment 126
The use of analytics to drive sales force approaches 126
Content-driven interactions between sales reps and customers 126
To what extent will the sales model change in the immediate future? 127
Designing a marketing and sales function that is fit for the future 129

Chapter 7

Appendix

Bibliography 134
Index 136

List of Figures

Figure 1.1: Projected revenue losses ($bn) due to patent expirations, 2007e-2012p 19
Figure 1.2: R&D investment ($bn) in the US, 2004-2007 21
Figure 1.3: FDA new drug approvals, 2000-2008 22
Figure 1.4: Global pharma market growth slowdown 24
Figure 1.5: Survey of US medical practices, February 2009 28
Figure 1.6: US sales force size - top 30 companies, 1997-2007 32
Figure 1.7: Pharma sales rep funnel 34
Figure 2.8: Field force: Sales, cost and profit impact 47
Figure 2.9: The impact of three different sizing scenarios on company profits 50
Figure 2.10: Physician segmentation enabling effective targeting 54
Figure 2.11: Modeling doctors’ prescribing behavior 58
Figure 3.12: The training trade-off 71
Figure 3.13: Effective sales force training responds to a new selling environment 73
Figure 3.14: Sales rep characteristics with the most influence on physician satisfaction 74
Figure 3.15: Implications for future sales force training 76
Figure 4.16: Sales force restructuring and innovation - State of the industry 89
Figure 4.17: The expected shift in marketing and sales efforts 91
Figure 4.18: Implications for pharma companies on the path to KAM 94
Figure 5.19: e-Detailing as part of the multi-channel approach to CRM 109
Figure 5.20: CLM feedback loop 112
Figure 5.21: TGaS survey on CLM implementation among top pharma companies, 2007-2008 114
Figure 6.22: Sampling trends %, 2008 124
Figure 6.23: Readiness for new business models in the next two years 128
Figure 6.24: Future organization of the pharmaceutical marketing and sales function 130
List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Blockbusters going off-patent 2010-2012</td>
<td>20</td>
</tr>
<tr>
<td>1.2</td>
<td>Planned job cuts by big pharmaceutical companies, October 2008</td>
<td>35</td>
</tr>
<tr>
<td>2.3</td>
<td>Target return-per-call method in eight steps by Zoltners &amp; Sinha</td>
<td>44</td>
</tr>
<tr>
<td>2.4</td>
<td>Comparison of sales force sizing methods</td>
<td>45</td>
</tr>
<tr>
<td>3.5</td>
<td>Common pharmaceutical sales force training settings</td>
<td>70</td>
</tr>
<tr>
<td>5.6</td>
<td>How tablet PCs support sales force activities</td>
<td>110</td>
</tr>
<tr>
<td>6.7</td>
<td>New approaches to marketing and sales challenges</td>
<td>127</td>
</tr>
</tbody>
</table>